CD8A and metabolic dysfunction-associated steatotic liver disease: In the DILI group, the most striking result was the increase in CD69+ and HLA-DR+ in both CD4+ and CD8+ T cells, which may be used as a biomarker to differentiate between NAFLD and DILI patients, particularly in those presenting mild-to-moderate elevations in transaminases.